Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06418789 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Study acronym: GERMAN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This is a prospective, single-center, non-randomized phase II study. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy as second-line drug therapy for patients with advanced germ cell tumors.
Trial Details
NCT Number NCT06418789
Lead Sponsor N.N. Petrov National Medical Research Center of Oncology
Conditions
(from sponsor)		 Germ Cell Tumor
Related terms Choriocarcinoma, Endodermal Sinus Tumor, Germinoma, Neoplasms, Germ Cell and Embryonal, Nonseminomatous germ cell tumor, Seminoma, Teratoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov